<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974385</url>
  </required_header>
  <id_info>
    <org_study_id>HSR210190</org_study_id>
    <nct_id>NCT04974385</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine Versus Non-liposomal Bupivacaine for Total Shoulder Arthroplasty</brief_title>
  <official_title>Comparison of Liposomal Bupivacaine Versus Non-liposomal Bupivacaine for Total Shoulder Arthroplasty: a Prospective, Double-blinded, Noninferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to validate the analgesic efficacy of admixed Liposomal&#xD;
      bupivacaine (LB) + bupivacaine compared with plain bupivacaine when injected for interscalene&#xD;
      nerve block (ISNB) for total shoulder arthroplasty (TSA). We hypothesize that admixed LB will&#xD;
      be non-inferior to plain bupivacaine in terms of postoperative opioid consumption following&#xD;
      TSA. The primary outcome of this study will be opioid consumption over the first 72 hours&#xD;
      following surgery. Secondary outcomes will include: pain scores, opioid-related adverse&#xD;
      events, block related adverse events, pain related phone calls, pain related ED visits and&#xD;
      patient satisfaction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>72 hours postoperative</time_frame>
    <description>Morphine equivalents used during first 72 hours after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numeric Rating Scale Reported Pain Scores</measure>
    <time_frame>72 hours postoperative</time_frame>
    <description>Patient reported pain scores using the numeric rating scale from 0 to 10 where 0 means no pain and 10 means worst possible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nerve Block Related Adverse Events</measure>
    <time_frame>72 hours postoperative</time_frame>
    <description>Any adverse event determined to be caused as a result of having a nerve block to include but not limited to toxicity, allergic reaction, nerve injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with Additional, Unanticipated Pain Related Medical Encounters</measure>
    <time_frame>72 hours postoperative</time_frame>
    <description>Any unanticipated, unplanned, pain related phone calls to surgeon or anesthesiologist for rescue pain treatment, pain related emergency department visits or primary care physician visits for pain treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Satisfaction with Postoperative Pain Control Using the Numeric Rating Scale</measure>
    <time_frame>72 hours postoperative</time_frame>
    <description>Patient reported satisfaction with their postoperative pain control using the numeric rating scale from 0 to 10 where 0 means completely dissatisfied and 10 means completely satisfied</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group will receive ISNB with admixed LB (10 mL) and 0.5% bupivacaine (10 mL) total of 20 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator group will receive ISNB with 20 mL of 0.5% non-liposomal bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>Validate the analgesic efficacy of admixed LB + bupivacaine compared with plain bupivacaine when injected for ISNB for total shoulder arthroplasty.</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Active comparator as standard of care.</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_label>Non-liposomal Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults 18 years of age or older&#xD;
&#xD;
          -  Undergoing total shoulder arthroplasty&#xD;
&#xD;
          -  Willing and able to sign consent form to participate in study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years of age&#xD;
&#xD;
          -  Unwilling or unable to sign consent form to participate in study&#xD;
&#xD;
          -  Allergy to local anesthetic&#xD;
&#xD;
          -  Medical contraindication to interscalene nerve block&#xD;
&#xD;
          -  Chronic opioid use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald A Elmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donald A Elmer, MD</last_name>
    <phone>801-540-8295</phone>
    <email>dae9c@virginia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia Medical Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 3, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>D. Aric Elmer, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

